Skip to main content
. 2016 Sep 25;22(3):339–349. doi: 10.3350/cmh.2016.0021

Figure 4.

Figure 4.

Differences in HCC development according to cirrhosis (A), BMI (B), diabetes mellitus/dyslipidemia/hypertension/metabolic syndrome (C), WHR (D), VFA (E), and hepatic steatosis (F) in CHB patients treated with entecavir. HCC, hepatocellular carcinoma; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; MS, metabolic syndrome; WHR, waist-hip-ratio; VFA, visceral fat area; CHB, chronic hepatitis B.